Efficacy and safety of luseogliflozin added to insulin therapy for 52-week in Japanese patients with T2DM

0 views
0 downloads

Powered byMorressier logo black

Discover more research and events on morressier.com

ImprintTerms of ServicePrivacy PolicyAccessibility